Shots:
- The P-III (SENTRY) trial assessed Selinexor (60mg, QW) + ruxolitinib vs PBO + ruxolitinib in 353 pts with frontline myelofibrosis; FDA discussions on SENTRY data & its sNDA strategy is underway, with potential compendia inclusion in H2’26
- As of Feb 20, 2026, trial met its first co-1EP, with 50% vs 28% achieving SVR35 at Wk. 24, showing rapid response at Wk. 12 (49% vs 20%) & sustained at Wk. 36 (47% vs 23%). Abs-TSS response was similar, with 9.89 vs 10.86-point improvement at 24wks.
- Trial also showed improved OS by >50% with follow-up ongoing; post-hoc analyses at Wks. 12 & 24 suggest SVR35 may predict OS, plus ≥20% VAF reduction was higher (32% vs 24%), with no meaningful differences seen in PFS, Hb stabilization, or bone marrow fibrosis
Ref: PRnewswire | Image: Karyopharm | Press Release
Related News: Apogee Therapeutics Reports Part A P-II (APEX) Maintenance Data on Zumilokibart in Atopic Dermatitis
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
